Radioimmunotherapy—a potential novel tool for pancreatic cancer therapy?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radioimmunotherapy—a potential novel tool for pancreatic cancer therapy?
Authors
Keywords
Pancreatic cancer, Radioimmunotherapy, Pre-targeting, Radioisotope, Monoclonal antibody
Journal
TUMOR BIOLOGY
Volume 36, Issue 6, Pages 4053-4062
Publisher
Springer Nature
Online
2015-04-29
DOI
10.1007/s13277-015-3479-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry
- (2014) Chanjuan Shi et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
- (2014) F. Al-Ejeh et al. CLINICAL CANCER RESEARCH
- Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA
- (2014) Ruth A Bryan et al. Expert Review of Anticancer Therapy
- The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
- (2014) J. B. Pasternack et al. JOURNAL OF NUCLEAR MEDICINE
- hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
- (2014) Stina Nordh WORLD JOURNAL OF GASTROENTEROLOGY
- Matching chelators to radiometals for radiopharmaceuticals
- (2013) Eric W. Price et al. CHEMICAL SOCIETY REVIEWS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases
- (2013) Daniel Ansari et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer
- (2012) Allyson J. Ocean et al. CANCER
- Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
- (2011) S. A. Gulec et al. CLINICAL CANCER RESEARCH
- Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer
- (2011) Michio Abe et al. Cancers
- Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma
- (2009) Asma Sultana et al. BMC CANCER
- Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10-90Y-IMP-288 Alone and Combined with Gemcitabine
- (2009) H. Karacay et al. JOURNAL OF NUCLEAR MEDICINE
- A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma
- (2008) D. V. Gold et al. CANCER RESEARCH
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started